SU9516

SU9516 is a potent CDK2 inhibitor, with an IC50 of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC50s of 40, 200 nM, respectively.

Product Specifications

CAS Number

[377090-84-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Autophagy; CDK

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/SU9516.html

Purity

99.85

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C1NC2=C(C=C(OC)C=C2)/C1=C/C3=CN=CN3

Molecular Formula

C13H11N3O2

Molecular Weight

241.25

Precautions

H302, H315, H319, H335

References & Citations

[1]Lane ME, et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 2001 Aug 15;61 (16) :6170-7.|[2]Yu B, et al. SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochem Pharmacol. 2002 Oct 1;64 (7) :1091-100.|[3]Gao N, et al. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1- (3H-imidazol-4-yl) -meth- (Z) -ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Mol Pharmacol. 2006 Aug;70 (2) :645-55.